Effect of Dietary Protein Restriction on Prognosis in Patients With Diabetic Nephropathy

Not Applicable

Completed

• Conditions: Type 1 Diabetes Mellitus With Diabetic Nephropathy
• Interventions: Dietary Supplement: low protein diet; Dietary Supplement: normal protein diet

• Registration Number: NCT01521910
• Lead Sponsor: Steno Diabetes Center Copenhagen

Brief Summary

The purpose of the investigators study was to determine the effect of dietary protein restriction on survival and progression to end stage renal disease (ESRD) in diabetic nephropathy.

Detailed Description

The study was a prospective, randomized, unmasked, controlled trial carried out at the Steno Diabetes Center. With concealed randomization the patients were (in blocks of two according to the level of GFR) assigned to receive either a usual-protein diet or a low-protein diet.

After randomization an iso-caloric low-protein diet of 0.6 g/kg/day was prescribed to patients in the low-protein diet group. The usual-pro tein diet consisted of the patients' pre-study diet.

The planned duration of follow-up was four years, scheduled visits every three-months. All patients gave complete history of medication, underwent examination of weight, urinary albumin-, sodium- and urea excretion, serum albumin, serum urea, hemoglobin, hemoglobin A1c, blood pressure, serum total-cholesterol, high-density lipoprotein (HDL) cholesterol.

GFR, serum triglycerides,calcium and phosphorous, anthropometric measurements, nutritional status and smoking habits were evaluated every six months.

Dietary protein intake was estimated on the basis of three consecutive 24-hour urine samples completed before each visit, using urinary excretion of urea nitrogen.

GFR was measured by plasma clearance of 51Cr-EDTA over a 4 hour period and standardized for 1.73m2 body surface area using the same surface for each patient during the study.

Study Timeline

• Study Start: 1995-04
• Primary Completion: 2000-06
• Study Completion: 2000-06
• Status Verified: 2012-01
• Study First Submitted: 2012-01-13
• Study First Submitted QC: 2012-01-30
• Last Update Submitted: 2012-01-30
• Study First Posted: 2012-01-31
• Last Update Posted: 2012-01-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

• Diabetes mellitus type 1
• duration at least 10 years
• onset before age of 35,
• presence of diabetic retinopathy
• albuminuria>=300mg/24 h in at least 2/3 sterile urine samples
• no clinical or laboratory evidence of other kidney or urinary tract disease
• GFR above 20mL/min/1.73M2
• pre-study decline in GFR>= 2 mL/min/year

Exclusion Criteria

• pregnancy
• history of congestive heart failure or myocardial infarction or coronary bypass surgery within the last three months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Low protein diet	low protein diet	-
Normal protein diet	normal protein diet	-

Primary Outcome Measures

Name	Time	Method
Rate of decline of GFR	4 years	rate of decline was measured if the patient had a minimum of one year of follow up and a minimum of 3 GFR measures during the study. All measures of GFR during the study period (including baseline) were used to calculate the rate of decline(the slopes) of GFR. GFR was measured every 6 months during the 4 years of follow up.
Cumulative incidence of ESRD requiring dialysis or transplantation, and death	4 years	Cause of death was obtained from death certificate by an independent observer. Before the development of uremic symptoms, patients were referred to the department of nephrology at the University Hospital of Herlev or Rigshospitalet, when GFR deteriorated below 10 to 20 ML/min/1.73m2, where accepted criteria for initiation of dialysis and transplantation were applied on patients from both diet groups. Patients continued their scheduled visits and treatment in the study until the end of the four-year follow up.; This was assesed every 3 months until the end of the 4 year follow up period.

Trial Locations

Locations (1)

Steno Diabetes Center; 🇩🇰 Gentofte, Denmark